SCHEMBL568073

SCHEMBL568073

COC(=O)C1CCN(S(=O)(=O)c2ccc3cnccc3c2)CC1

nearest known ligand 0.62

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
PKM P14618 1/20 0.62
KMT2A Q03164 4/20 0.54
JAK2 O60674 2/20 0.51
ROCK2 O75116 2/20 0.51
ROCK1 Q13464 2/20 0.51
JAK3 P52333 1/20 0.51
F10 P00742 1/20 0.50
USP2 O75604 1/20 0.50
LMNA P02545 1/20 0.50
TSHR P16473 1/20 0.50
MAPK1 P28482 1/20 0.50
HSD17B10 Q99714 1/20 0.50
TDP1 Q9NUW8 1/20 0.49
HTT P42858 1/20 0.49
AKR1C3 P42330 1/20 0.48
AKR1C1 Q04828 1/20 0.48
POLB P06746 1/20 0.48
NPC1 O15118 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL567229 0.99 PKM (0.61) PKMKMT2AJAK2ROCK2ROCK1
SCHEMBL14125421 0.85 PKM (0.69) PKMKMT2AUSP2LMNATSHR
SCHEMBL10167433 0.83 LMNA (0.51) KMT2AJAK2ROCK2ROCK1JAK3
SCHEMBL567398 0.80 NAMPT (0.52) PKMJAK2ROCK2ROCK1JAK3
SCHEMBL567640 0.79 NAMPT (0.51) PKMKMT2AJAK2ROCK2ROCK1
Hydrochloric Acid SCHEMBL567326 0.79 NAMPT (0.51) PKMJAK2ROCK2ROCK1JAK3
SCHEMBL566198 0.78 AKR1C3 (0.50) JAK2ROCK2ROCK1JAK3F10
SCHEMBL566197 0.78 AKR1C3 (0.50) JAK2ROCK2ROCK1JAK3F10
SCHEMBL23246047 0.77 PKM (0.61) PKMKMT2ALMNAHTTPOLB
SCHEMBL566183 0.77 LMNA (0.46) PKMJAK2ROCK2ROCK1JAK3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2444395-B1 SUBSTITUTED ISOQUINOLINE DERIVATIVE WESTERN THERAPEUTICS INST INC D (JP) 2016-01-06 EP claimed
US-8951997-B2 Substituted isoquinoline derivative D. WESTERN THERAPEUTICS INSTITUTE, INC. (JP) 2015-02-10 US claimed
EP-2444395-A1 SUBSTITUTED ISOQUINOLINE DERIVATIVE D. Western Therapeutics Institute, Inc. (JP) 2012-04-25 EP claimed
US-20120035159-A1 SUBSTITUTED ISOQUINOLINE DERIVATIVE D. WESTERN THERAPEUTICS INSTITUTE, INC (JP) 2012-02-09 US claimed
EP-2444395-B1 SUBSTITUTED ISOQUINOLINE DERIVATIVE WESTERN THERAPEUTICS INST INC D (JP) 2016-01-06 EP disclosed
EP-2444395-B1 SUBSTITUTED ISOQUINOLINE DERIVATIVE WESTERN THERAPEUTICS INST INC D (JP) 2016-01-06 EP disclosed
US-8951997-B2 Substituted isoquinoline derivative D. WESTERN THERAPEUTICS INSTITUTE, INC. (JP) 2015-02-10 US disclosed
US-8951997-B2 Substituted isoquinoline derivative D. WESTERN THERAPEUTICS INSTITUTE, INC. (JP) 2015-02-10 US disclosed
EP-2444395-A1 SUBSTITUTED ISOQUINOLINE DERIVATIVE D. Western Therapeutics Institute, Inc. (JP) 2012-04-25 EP disclosed
US-20120035159-A1 SUBSTITUTED ISOQUINOLINE DERIVATIVE D. WESTERN THERAPEUTICS INSTITUTE, INC (JP) 2012-02-09 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120035159-A1 SUBSTITUTED ISOQUINOLINE DERIVATIVE SULT1A1, SULT1E1, SULT2A1 PKM 3496/4885KMT2A 1007/4885JAK2 575/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.